Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Touts Galvus Efficacy Vs. Januvia After Metformin Comparison Fails

Executive Summary

Novartis is highlighting the superior efficacy of its dipeptidyl peptidase-4 inhibitor Galvus relative to Merck's recently launched DPP-4 agent Januvia.

You may also be interested in...



Galvus “Approvable”: Additional Trial To Be Relatively Small, Short – Novartis

FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said

Galvus “Approvable”: Additional Trial To Be Relatively Small, Short – Novartis

FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said

Merck Ups Marketing Spend For Januvia And Gardasil As Competitors Stumble

Merck's decision to step up marketing spend for two of its new products, the DPP-4 inhibitor Januvia for diabetes and the human papilloma virus vaccine Gardasil,may reflect an effort to take advantage of delays in the launches of potential competitor products

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS047809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel